Recombinant interferon alfa therapy in chronic hepatitis C
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 1995; 5 (1): 32-4
en Inglés
| IMEMR
| ID: emr-95777
ABSTRACT
In an open, non-comparative trial efficacy and safety of Recombinant interferon alfa [INF alfa] given in 3 million units subcutaneously thrice weekly for 6 months was assessed in patients with chronic hepatitis C. A response rate of 58.7% at the end of treatment period and relapse rate of 47.4% after cessation of treatment was noted
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Biopsia
/
Interferón Tipo I
/
Enfermedad Crónica
/
Anticuerpos contra la Hepatitis C
/
Pruebas de Función Hepática
Idioma:
Inglés
Revista:
J. Coll. Physicians Surg. Pak.
Año:
1995
Similares
MEDLINE
...
LILACS
LIS